Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising investor worries over the company’s near-term commercial outlook. Ivonescimab, one of the most closely watched innovative drugs emerging from China, did not establish “substantial evidence of effectiveness”, said US firm Summit Therapeutics, which has the exclusive rights to develop and commercialise the drug in global...
Health
Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback
The Perspectives
0 verified voices · Three viewpoints · Real discourse
Only verified Neural Identity holders can participate in The Perspectives.
Sign In with Neural Identity
Left
0
Be the first to share a left perspective
Center
0
Be the first to share a center perspective
Right
0
Be the first to share a right perspective